Comments
Loading...

Arrowhead Pharma Analyst Ratings

ARWRNASDAQ
Logo brought to you by Benzinga Data
$15.47
0.382.48%
At close: -
$15.47
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$80.00
Lowest Price Target1
$24.00
Consensus Price Target1
$47.53

Arrowhead Pharma Analyst Ratings and Price Targets | NASDAQ:ARWR | Benzinga

Arrowhead Pharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Arrowhead Pharma Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
3
2
Nov 24
3
Dec 24
1
Jan
4
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.1
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

B. Riley Securities
HC Wainwright & Co.
RBC Capital
Chardan Capital
Bernstein

1calculated from analyst ratings

Analyst Ratings for Arrowhead Pharma

Buy NowGet Alert
02/14/2025Buy Now—B. Riley Securities
Mayank Mamtani71%
$51 → $38ReiteratesBuy → BuyGet Alert
02/12/2025Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$80 → $80ReiteratesBuy → BuyGet Alert
02/11/2025Buy Now—RBC Capital
Luca Issi41%
$42 → $42ReiteratesOutperform → OutperformGet Alert
02/11/2025Buy Now—Chardan Capital
Keay Nakae58%
$60 → $60MaintainsBuyGet Alert
01/23/2025Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$80 → $80ReiteratesBuy → BuyGet Alert
12/20/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$80 → $80ReiteratesBuy → BuyGet Alert
12/12/2024Buy Now—Chardan Capital
Keay Nakae58%
$60 → $60MaintainsBuyGet Alert
12/03/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$60 → $80MaintainsBuyGet Alert
11/29/2024Buy Now—Bernstein
William Pickering44%
$27 → $24MaintainsMarket PerformGet Alert
11/27/2024Buy Now—Piper Sandler
Edward Tenthoff52%
$62 → $45MaintainsOverweightGet Alert
11/27/2024Buy Now—Citigroup
Shawn Egan52%
$27 → $26MaintainsNeutralGet Alert
11/27/2024Buy Now—Chardan Capital
Keay Nakae58%
$60 → $60MaintainsBuyGet Alert
11/20/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$60 → $60ReiteratesBuy → BuyGet Alert
10/11/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$60 → $60ReiteratesBuy → BuyGet Alert
10/08/2024Buy Now—Piper Sandler
Edward Tenthoff52%
$62 → $62ReiteratesOverweight → OverweightGet Alert
09/26/2024Buy Now—RBC Capital
Luca Issi41%
$42 → $42ReiteratesOutperform → OutperformGet Alert
09/09/2024Buy Now—Cantor Fitzgerald
Josh Schimmer54%
—Reiterates → OverweightGet Alert
09/05/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$60 → $60ReiteratesBuy → BuyGet Alert
09/03/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$60 → $60ReiteratesBuy → BuyGet Alert
08/12/2024Buy Now—B. Riley Securities
Mayank Mamtani71%
$55 → $55ReiteratesBuy → BuyGet Alert
07/23/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$60 → $60ReiteratesBuy → BuyGet Alert
07/17/2024Buy Now—Chardan Capital
Keay Nakae58%
$60 → $60MaintainsBuyGet Alert
07/05/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$90 → $60MaintainsBuyGet Alert
06/26/2024Buy Now—Chardan Capital
Keay Nakae58%
$60 → $60MaintainsBuyGet Alert
06/20/2024Buy Now—Cantor Fitzgerald
Alethia Young76%
—Reiterates → OverweightGet Alert
06/11/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$90 → $90ReiteratesBuy → BuyGet Alert
06/05/2024Buy Now—Goldman Sachs
Andrea Tan41%
→ $31Initiates → NeutralGet Alert
06/03/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$90 → $90ReiteratesBuy → BuyGet Alert
06/03/2024Buy Now—Chardan Capital
Keay Nakae58%
$60 → $60MaintainsBuyGet Alert
05/13/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$90 → $90ReiteratesBuy → BuyGet Alert
05/13/2024Buy Now—Morgan Stanley
Michael Ulz58%
$36 → $27MaintainsEqual-WeightGet Alert
05/10/2024Buy Now—Chardan Capital
Keay Nakae58%
$60 → $60MaintainsBuyGet Alert
02/08/2024Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$90 → $90ReiteratesBuy → BuyGet Alert
02/07/2024Buy Now—RBC Capital
Luca Issi41%
$50 → $50ReiteratesOutperform → OutperformGet Alert
02/07/2024Buy Now—Morgan Stanley
Michael Ulz58%
$34 → $36MaintainsEqual-WeightGet Alert
02/07/2024Buy Now—Citigroup
Shawn Egan52%
$33 → $34MaintainsNeutralGet Alert
01/16/2024Buy Now—RBC Capital
Luca Issi41%
$50 → $50ReiteratesOutperform → OutperformGet Alert
01/02/2024Buy Now—B of A Securities
Jason Gerberry63%
$29 → $37MaintainsBuyGet Alert
12/04/2023Buy Now—B of A Securities
Jason Gerberry63%
→ $29Initiates → BuyGet Alert
11/30/2023Buy Now—Morgan Stanley
Michael Ulz58%
$40 → $37MaintainsEqual-WeightGet Alert
11/30/2023Buy Now—RBC Capital
Luca Issi41%
→ $50ReiteratesOutperform → OutperformGet Alert
09/19/2023Buy Now—Citigroup
Shawn Egan52%
→ $33Initiates → NeutralGet Alert
08/09/2023Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
→ $90ReiteratesBuy → BuyGet Alert
08/08/2023Buy Now—Chardan Capital
Keay Nakae58%
→ $60ReiteratesBuy → BuyGet Alert
08/08/2023Buy Now—Cantor Fitzgerald
Alethia Young76%
$79 → $47MaintainsOverweightGet Alert
08/08/2023Buy Now—RBC Capital
Luca Issi41%
→ $60ReiteratesOutperform → OutperformGet Alert
07/21/2023Buy Now—TD Cowen
Brendan Smith36%
—Initiates → OutperformGet Alert
07/20/2023Buy Now—B. Riley Securities
Mayank Mamtani71%
→ $55ReiteratesBuy → BuyGet Alert
06/30/2023Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
→ $90ReiteratesBuy → BuyGet Alert
06/06/2023Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
→ $90ReiteratesBuy → BuyGet Alert
06/02/2023Buy Now—Piper Sandler
Edward Tenthoff52%
$52 → $59MaintainsOverweightGet Alert
06/02/2023Buy Now—Chardan Capital
Keay Nakae58%
→ $60ReiteratesBuy → BuyGet Alert
05/24/2023Buy Now—Chardan Capital
Keay Nakae58%
→ $60ReiteratesBuy → BuyGet Alert
05/12/2023Buy Now—SVB Leerink
Mani Foroohar46%
→ $40DowngradeOutperform → Market PerformGet Alert
05/03/2023Buy Now—RBC Capital
Luca Issi41%
→ $60Reiterates → OutperformGet Alert
05/03/2023Buy Now—Goldman Sachs
Madhu Kumar72%
$65 → $73MaintainsBuyGet Alert
05/03/2023Buy Now—Morgan Stanley
Michael Ulz58%
$37 → $40MaintainsEqual-WeightGet Alert
04/26/2023Buy Now—SMBC Nikko
David Hoang42%
→ $80Initiates → OutperformGet Alert
04/12/2023Buy Now—SVB Securities
Mani Foroohar46%
$21 → $35UpgradeMarket Perform → OutperformGet Alert
03/21/2023Buy Now—Bernstein
William Pickering44%
→ $27Initiates → Market PerformGet Alert
02/10/2023Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
→ $90Reiterates → BuyGet Alert
02/10/2023Buy Now—Chardan Capital
Keay Nakae58%
→ $60Reiterates → BuyGet Alert
02/08/2023Buy Now—B. Riley Securities
Mayank Mamtani71%
$59 → $55MaintainsBuyGet Alert
02/07/2023Buy Now—RBC Capital
Luca Issi41%
$83 → $77MaintainsOutperformGet Alert
02/07/2023Buy Now—Baird
Joel Beatty68%
$60 → $58MaintainsOutperformGet Alert
02/07/2023Buy Now—Piper Sandler
Edward Tenthoff52%
$55 → $52MaintainsOverweightGet Alert
12/06/2022Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$110 → $90MaintainsBuyGet Alert
11/30/2022Buy Now—B. Riley Securities
Mayank Mamtani71%
$65 → $59MaintainsBuyGet Alert
11/29/2022Buy Now—Jefferies
Maury Raycroft31%
$92 → $75MaintainsBuyGet Alert
11/29/2022Buy Now—Morgan Stanley
Andrew Galler33%
$41 → $37MaintainsEqual-WeightGet Alert
11/29/2022Buy Now—SVB Leerink
Mani Foroohar46%
$33 → $31MaintainsMarket PerformGet Alert
11/10/2022Buy Now—Piper Sandler
Edward Tenthoff52%
$72 → $64MaintainsOverweightGet Alert
11/10/2022Buy Now—SVB Leerink
Mani Foroohar46%
$32 → $33MaintainsMarket PerformGet Alert
09/09/2022Buy Now—Morgan Stanley
Andrew Galler33%
→ $41Initiates → Equal-WeightGet Alert
08/08/2022Buy Now—Goldman Sachs
Madhu Kumar72%
$58 → $65MaintainsBuyGet Alert
06/03/2022Buy Now—HC Wainwright & Co.
Patrick Trucchio47%
$100 → $110MaintainsBuyGet Alert
05/24/2022Buy Now—Goldman Sachs
Madhu Kumar72%
$90 → $66MaintainsBuyGet Alert
05/11/2022Buy Now—Chardan Capital
Keay Nakae58%
$94 → $80MaintainsBuyGet Alert
05/11/2022Buy Now—Piper Sandler
Edward Tenthoff52%
$89 → $72MaintainsOverweightGet Alert
05/11/2022Buy Now—Baird
Joel Beatty68%
$71 → $60UpgradeNeutral → OutperformGet Alert
05/11/2022Buy Now—SVB Leerink
Mani Foroohar46%
$36 → $35MaintainsMarket PerformGet Alert

FAQ

Q

What is the target price for Arrowhead Pharma (ARWR) stock?

A

The latest price target for Arrowhead Pharma (NASDAQ:ARWR) was reported by B. Riley Securities on February 14, 2025. The analyst firm set a price target for $38.00 expecting ARWR to rise to within 12 months (a possible 145.64% upside). 32 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arrowhead Pharma (ARWR)?

A

The latest analyst rating for Arrowhead Pharma (NASDAQ:ARWR) was provided by B. Riley Securities, and Arrowhead Pharma reiterated their buy rating.

Q

When was the last upgrade for Arrowhead Pharma (ARWR)?

A

The last upgrade for Arrowhead Pharmaceuticals Inc happened on April 12, 2023 when SVB Securities raised their price target to $35. SVB Securities previously had a market perform for Arrowhead Pharmaceuticals Inc.

Q

When was the last downgrade for Arrowhead Pharma (ARWR)?

A

The last downgrade for Arrowhead Pharmaceuticals Inc happened on May 12, 2023 when SVB Leerink changed their price target from N/A to $40 for Arrowhead Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Arrowhead Pharma (ARWR)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arrowhead Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arrowhead Pharma was filed on February 14, 2025 so you should expect the next rating to be made available sometime around February 14, 2026.

Q

Is the Analyst Rating Arrowhead Pharma (ARWR) correct?

A

While ratings are subjective and will change, the latest Arrowhead Pharma (ARWR) rating was a reiterated with a price target of $51.00 to $38.00. The current price Arrowhead Pharma (ARWR) is trading at is $15.47, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch